Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD).
Journal: American heart journal
Published: November 03, 2017
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.
Journal: The New England journal of medicine
Published: August 29, 2017
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.
Journal: Lancet (London, England)
Published: July 17, 2017
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.
Journal: The Canadian journal of cardiology
Published: May 25, 2017
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
Published: June 02, 2015
Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
Journal: The American journal of cardiology
Published: December 10, 2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Journal: American heart journal
Published: May 12, 2014
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER).
Journal: American heart journal
Published: April 09, 2014
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
Journal: European heart journal. Acute cardiovascular care
Published: March 15, 2014
Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
Journal: The American journal of cardiology
Published: March 03, 2014
Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
Journal: The American journal of cardiology
Published: September 17, 2013
Last Updated: 09/26/2026